CrystalGenomics Confirms Complete Remission of Blood Cancer Treatment 'CG-806'

[Asia Economy Reporter Hyunseok Yoo] CrystalGenomics announced on the 24th that complete response, indicating the complete disappearance of tumors, was confirmed in the Phase 1 clinical trial of the world's first (First in class) blood cancer treatment ‘CG-806’ for patients with acute myeloid leukemia (AML).

According to the annual report of Aptose Biosciences in the United States on the 23rd (local time), complete response was observed in patients who were administered 450mg of the blood cancer treatment CG-806 twice daily (BID). It was also reported to be safe without side effects in patients who received multiple doses.

At the American Society of Hematology (ASH) held last December, anti-leukemia activity was observed in one FLT3-positive patient (AML) who had undergone repeated chemotherapy. It was announced that the peripheral blood progenitor cell count (diagnosed as leukemia at 25% or higher) decreased from 93% to 10% during the first treatment cycle.

Currently, 30 hospitals in the United States are enrolling patients with acute myeloid leukemia to receive 450mg. Complete response has been observed at the 450mg dose level. No toxicity trends that could hinder dose escalation have been observed, so the dose will be increased to 600mg, the next dose level.

CG-806 is the world's first disease-targeting FLT3/BTK multi-inhibitor drug candidate developed by CrystalGenomics.

In August last year, Stonelake Capital in the United States analyzed that CG-806 would have a stronger effect than AbbVie's Ibrutinib, a blockbuster drug with annual sales exceeding $7 billion (approximately 8 trillion KRW). Researcher Adam May stated in a report that after comparing the preclinical profiles of drugs such as AbbVie’s Ibrutinib and Merck’s ARQ-531 with CG-806, CG-806 showed greater potential as a blood cancer treatment.

The complete data from the Phase 1 clinical trial for acute myeloid leukemia is planned to be presented at the European Hematology Association (EHA) meeting this June.

This content was produced with the assistance of AI translation services.